Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2026 11:45 ET | Source: Tevogen Bio Inc

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Tevogen Bio announces $3 million PIPE financing with The Patel Family, LLP to support growth initiatives and future revenue opportunities.
October 18, 2024 22:46 ET | Source: Tevogen Bio Inc

Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days

WARREN, N.J., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) is a clinical-stage specialty immunotherapy biotech developing off-the-shelf,...
July 08, 2024 16:07 ET | Source: Tevogen Bio Inc

Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility

WARREN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Ryan Saadi, MD, MPH, founding CEO of Tevogen Bio (“Tevogen”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing...
March 28, 2024 08:05 ET | Source: Tevogen Bio Inc

Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price

The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.
March 27, 2024 09:20 ET | Source: Tevogen Bio Inc

Tevogen Bio Announces Series A-1 Preferred Stock Investment

The shares of Series A-1 Preferred Stock will be issued in the first quarter and will be convertible at a conversion price of $10.00, as opposed to the $4.